Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients-Reference-Cited by-同舟云学术

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Published:2015-10-22 Issue:11 Volume:113 Page:1571-1580
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Donskov Frede,Michaelson M Dror,Puzanov Igor,Davis Mellar P,Bjarnason Georg A,Motzer Robert J,Goldstein David,Lin Xun,Cohen Darrel P,Wiltshire Robin,Rini Brian I

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2015368.pdf

Reference42 articles.

1. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2012) Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118: 1252–1259.

2. Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJ, Powles T (2014) Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur Urol 65: 766–777.

3. Carus A, Gurney H, Gebski V, Harnett P, Hui R, Kefford R, Wilcken N, Ladekarl M, von der Maase H, Donskov F (2013) Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: assessment of chemotherapy for resolution of unfavourable neutrophilia. J Transl Med 11: 189.

4. Dechend R, Luft FC (2008) Angiogenesis factors and preeclampsia. Nature Med 14: 1187–1188.

5. Dienstmann R, Braña I, Rodon J, Tabernero J (2011) Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 16: 1729–1740.

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of the response to antiangiogenic sunitinib therapy by non-invasive hybrid diffuse optics in renal cell carcinoma;Biomedical Optics Express;2024-09-06

2. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

3. Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study;Molecular Cancer;2024-08-09

4. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial;BMC Cancer;2024-02-24

5. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers;Drug Resistance Updates;2023-03